Subcutaneous Lecanemab Maintenance Dosing for Alzheimer's Supported by New Data

(Medage today) – Toronto – A sought -after subcutaneous auto -injector has shown an efficiency and safety comparable to Formulation IV of Lecanemab (Leqembi) for maintenance treatment in early Alzheimer’s disease, researchers said here. Following …